Holen Sie sich die Stockscreener-App
252.37
0.27%
-0.4956
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$252.87
Offen:
$250.08
24-Stunden-Volumen:
495.92K
Relative Volume:
0.49
Marktkapitalisierung:
$36.77B
Einnahmen:
$5.40B
Nettoeinkommen (Verlust:
$1.49B
KGV:
24.95
EPS:
10.1168
Netto-Cashflow:
$1.78B
1W Leistung:
-2.02%
1M Leistung:
-8.61%
6M Leistung:
-9.67%
1J Leistung:
+8.50%
1-Tages-Spanne:
$246.17
$252.62
1-Wochen-Bereich:
$246.17
$260.22
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
252.44 | 36.84B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
486.41 | 174.07B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
164.50 | 47.54B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.58 | 39.64B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
42.63 | 35.57B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
First Trust Advisors LP Buys 329,588 Shares of ResMed Inc. $RMD - MarketBeat
Neuberger Berman Group LLC Boosts Position in ResMed Inc. $RMD - MarketBeat
Blair William & Co. IL Trims ResMed Inc. Stake - National Today
Dimensional Fund Advisors LP Has $231.59 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Blair William & Co. IL - MarketBeat
Crossmark Global Holdings Inc. Purchases 17,487 Shares of ResMed Inc. $RMD - MarketBeat
Marietta Investment Partners LLC Invests $2.70 Million in ResMed Inc. $RMD - MarketBeat
Resmed director Farrell sells $520k in stock - Investing.com India
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
ResMed Director Peter Farrell Plans Modest Insider Share Sale Under Rule 144 - TipRanks
ResMed (NYSE:RMD) Director Peter Farrell Sells 2,000 Shares - MarketBeat
ResMed Inc. $RMD Shares Sold by Victory Capital Management Inc. - MarketBeat
Quantbot Technologies LP Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Purchased by Fisher Asset Management LLC - MarketBeat
ResMed Updates CDI Count Amid Cross-Market Transfers and Buybacks - TipRanks
ResMed CFO Sandercock Sells 1,000 Shares Under Pre-Set Trading Plan - TipRanks
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
ResMed Executive Files Rule 144 Notice for Routine Share Sales - TipRanks
ResMed (NYSE: RMD) CFO sells 1,000 shares in Rule 10b5-1 trade - Stock Titan
Final Trades: Toast, Disney, ServiceNow and ResMed - CNBC
Mitsubishi UFJ Asset Management Increases ResMed Stake - National Today
Elo Mutual Pension Insurance Co Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach - Koreabizwire
Resmed Reveals Growing Global Awareness of Sleep Health Amid Action Gap in Latest Survey Findings - Quiver Quantitative
Resmed, Inc. - Via Ritzau
Andra AP fonden Cuts Stake in ResMed Inc. - National Today
RMD (NYSE: RMD) broker files Rule 144 notice for 1,000 shares - Stock Titan
Sleep apnea specialist Resmed announces plans for major new distribution centre - Mugglehead Investment Magazine
ResMed Inc. (RMD) Stock Analysis: Exploring a 16% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Andra AP fonden Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc.: The Sleep-Tech Stock You Should Not Ignore in 2026 - AD HOC NEWS
RMD PE Ratio & Valuation, Is RMD Overvalued - Intellectia AI
RMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ResMed Greenwood Hub Aims To Tighten Supply Chain And Patient Access - Sahm
Mitsubishi UFJ Asset Management Increases Stake in ResMed - National Today
Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in ResMed Inc. $RMD - MarketBeat
Intech Investment Management LLC Has $8.57 Million Holdings in ResMed Inc. $RMD - MarketBeat
Sleep Tech Demand Fuels ResMed - AlphaStreet News
ResMed Expands Greenwood Hub As Investors Weigh Valuation And Soft Momentum - Yahoo Finance
ResMed Inc (NYSE:RMD): A Durable Dividend Stock Built on Financial Strength - ChartMill
The Bull Case For ResMed (RMD) Could Change Following New Greenwood Distribution Hub Plan – Learn Why - simplywall.st
Dakota Wealth Management Grows Stake in ResMed Inc. $RMD - MarketBeat
Is ResMed Stock A Trap Or A Missed Opportunity? - Trefis
Why I would buy ResMed and these quality blue chips now - The Motley Fool Australia
Is ResMed Stock Poised for a Rally? - Trefis
Shares of Resmed Fall 3% After Declaring Plan to Open New US Distribution Center - marketscreener.com
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Resmed to open new distribution center in Indiana - MassDevice
ResMed Greenwood Hub Aims To Tighten Logistics And Support Growth - simplywall.st
Braun: Resmed to build $30 million facility in Greenwood - Fox 59
ResMed Inc (RMD) Shares Gap Down to $251.69 on Feb 24 - GuruFocus
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):